Émeline Tabouret

Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial

P12.59.B CONDITIONAL SURVIVAL ANALYSIS IN IDH-MUTANT HIGH-GRADE GLIOMAS: AN USEFUL TOOL IN CLINICAL PRACTICE

BIOS-01. CONDITIONAL SURVIVAL ANALYSIS IN IDH-MUTANT HIGH-GRADE GLIOMAS: AN USEFUL TOOL IN CLINICAL PRACTICE

Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients

European Association of Neuro-Oncology guideline on molecular testing of meningiomas for targeted therapy selection

Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma

Radioligand therapies in meningioma: Evidence and future directions

3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas

Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419)

3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas.

Challenges in glioblastoma research: focus on the tumor microenvironment

Diagnosis and Treatment of Pineal Region Tumors in Adults: A EURACAN Overview

Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults

Intravenous high‐dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An <scp>LOC</scp> network study

Olaparib in recurrent IDH-mutant high-grade glioma (OLAGLI).

SCENITH: A Flow Cytometry-Based Method to Functionally Profile Energy Metabolism with Single-Cell Resolution

Management and outcome of primary CNS lymphoma in the modern era

Clinical Management of Diffuse Low-Grade Gliomas

CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas

PL1.1 CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDHmutant gliomas

Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort

MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study